|1.||Sergeeva, S A: 2 articles (08/2009 - 11/2007)|
|2.||Bernoulli, J: 1 article (04/2014)|
|3.||Konkol, Y: 1 article (04/2014)|
|4.||Yatkin, E: 1 article (04/2014)|
|5.||Vuorikoski, H: 1 article (04/2014)|
|6.||Grigor'ev, M É: 1 article (09/2012)|
|7.||Gudkov, A V: 1 article (08/2009)|
|8.||Dugina, Yu L: 1 article (08/2009)|
|9.||Kachanova, M V: 1 article (08/2009)|
|10.||Kazikhinurov, R A: 1 article (08/2009)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
08/01/2009 - "The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of the disease, improved urodynamic parameters, and increased quality of life. "
08/01/2009 - "Clinical study of the efficiency and safety of afala in patients with benign prostatic hyperplasia."
05/01/2009 - "Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination. "
09/01/2012 - "The double-blind, placebo-controlled, randomized clinical trial involving 94 patients has evaluated the efficacy and safety of domestic preparation afala in patients with symptoms of I-II stages benign prostatic hyperplasia (BPH). "
08/01/2009 - "Afala therapy is indicated for patients with stage I-II benign prostatic hyperplasia of moderately pronounced symptoms."
08/01/2009 - "The use of afala in complex treatment of patients with chronic prostatitis improves the efficiency of therapy and prolongs its positive results. "
08/01/2009 - "Afala is indicated for patients with stages II and IIIa chronic prostatitis from the first day of therapy."
08/01/2009 - "Efficiency of afala in complex therapy of patients with chronic prostatitis."
08/01/2009 - "The efficiency of afala in the therapy of chronic abacterial prostatitis was demonstrated. "
08/01/2009 - "Clinical use of afala in the therapy of chronic prostatitis."
04/01/2014 - "In the hormone-dependent prostate inflammation model induced by implantation of slow-releasing pellets (50 mg testosterone and 5 mg estradiol) to Noble male rats, intragastric administration of Afala at a dose of 7.5 ml/kg for 18 weeks reduced the number of inflamed prostatic acini. "
04/01/2014 - "Effects of afala and antiestrogen ICI 182,780 in the model of hormone-dependent prostate inflammation."
|4.||Body Weight (Weight, Body)
|1.||Prostate-Specific Antigen (Semenogelase)
|5.||Estrogen Receptor Modulators (Antiestrogen)